Organisation paid for research Program year 2025 Source: CMS Open Payments

Temple University

Neither a doctor nor a teaching hospital

Research payments

$7,389,814

648 payments

Through program year 2025, Temple University is reported as receiving $7,389,814 in research payments, across 648 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$551,619	142
2024	Research	$820,556	181
2023	Research	$163,363	32
2022	Research	$726,231	38
2021	Research	$2,400,420	59
2020	Research	$2,121,088	90
2019	Research	$606,537	106

Breakdown

Who paid Research payments · program years 2019–2025

Gilead Sciences, Inc. $2,063,920 32 payments
Novartis Pharmaceuticals Corporation $1,930,048 18 payments
GlaxoSmithKline, LLC. $534,453 141 payments
Merck Sharp & Dohme Corporation $516,298 53 payments
Mitsubishi Tanabe Pharma America, Inc. $331,959 9 payments
Genentech, Inc. $316,146 52 payments
Cerus Corporation $269,860 19 payments
Gyrus ACMI, Inc. $193,741 13 payments
Hoffmann-La Roche Limited $189,532 15 payments
PolyNovo North America LLC $165,689 117 payments

Studies the money was for Research payments · program years 2019–2025

A Two-Year, Phase III Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 MG S.C. Secukinumab Versus Placebo, in Combination With Soc Therapy, in Patients With Active Lupus Nephritis $1,822,582 5 payments
The Simple Study - Subjects with Mild to Moderate Coronavirus Infection $547,920 1 payment
The Simple Study - Subjects with Mild to Moderate Coronavirus Infection $467,063 1 payment
Effect of Multidisciplinary and Traditional Non-Multidisciplinary Care Paradigms on Healthcare Outcomes, Quality of Life and Cost $321,001 5 payments
The Simple Study in Coronavirus, Severe Subjects $217,451 1 payment
The Spiration Valve System (SVS) Post-Market Registry Study for Severe Emphysema $183,787 5 payments
An Open Label Randomized Multicenter Study to Investigate Pharmacokinetics Pharmacodynamics Safe $171,142 12 payments
Cp-003 $165,689 117 payments
The Simple Study in Coronavirus, Severe Subjects $156,901 1 payment
A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety ofSugammadex MK-8616 for the Reversal of Neuromuscular Blockade Induced by EitherRocuronium Bromide or Vecuronium Bromide in American Society of AnesthesiologistsASA Class 3 or 4 Subjects $153,552 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.